Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

ABSTRACT:

Background

Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel.

Methods

In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned.

Results

A total of 20,332 patients were followed for a mean of 2.5 y

SUBMITTER: Sacco RL 

PROVIDER: S-EPMC2714259 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature